Chiltern Selected as Partner CRO

Article

Applied Clinical Trials

Chiltern announces it was selected as the partner CRO for Karolinska Development

Chiltern announces it was selected as the partner CRO for Karolinska Development, a publicly-traded life sciences investment company that brings selects and develops the most commercially attractive medical innovations to the point of sales or out-licensing to other companies. The extensive CRO selection process began in 2012 and the company states it was selected based on its compatibility with Karolinska's needs for global infrastructure, and approach to deliver on innovation, quality and flexibility.

Read the full release here.

Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Applied Clinical Trials and LabConnect
Cat Hall endpoint Clinical
Related Content
© 2024 MJH Life Sciences

All rights reserved.